408 related articles for article (PubMed ID: 25109893)
21. Immunotherapy for multiple myeloma.
Rosenblatt J; Bar-Natan M; Munshi NC; Avigan DE
Expert Rev Hematol; 2014 Feb; 7(1):91-6. PubMed ID: 24417573
[TBL] [Abstract][Full Text] [Related]
22. Prospects of combining adoptive cell immunotherapy with bortezomib.
Pellom ST; Singhal A; Shanker A
Immunotherapy; 2017 Mar; 9(4):305-308. PubMed ID: 28303766
[No Abstract] [Full Text] [Related]
23. Immunotherapy strategies in multiple myeloma.
Bae J; Munshi NC; Anderson KC
Hematol Oncol Clin North Am; 2014 Oct; 28(5):927-43. PubMed ID: 25212890
[TBL] [Abstract][Full Text] [Related]
24. Cellular immunotherapy for plasma cell myeloma.
Garfall AL; Vogl DT; Weiss BM; Stadtmauer EA
Bone Marrow Transplant; 2013 Nov; 48(11):1377-86. PubMed ID: 23645169
[TBL] [Abstract][Full Text] [Related]
25. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
Neri P; Bahlis NJ; Lonial S
Clin Cancer Res; 2016 Dec; 22(24):5959-5965. PubMed ID: 27797968
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.
Zahradova L; Mollova K; Ocadlikova D; Kovarova L; Adam Z; Krejci M; Pour L; Krivanova A; Sandecka V; Hajek R
Neoplasma; 2012; 59(4):440-9. PubMed ID: 22489700
[TBL] [Abstract][Full Text] [Related]
27. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
[TBL] [Abstract][Full Text] [Related]
28. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
[TBL] [Abstract][Full Text] [Related]
29. A mouse model for immunotherapy of myeloma.
Bogen B
Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
[TBL] [Abstract][Full Text] [Related]
30. Peptide-based immunotherapy for multiple myeloma: current approaches.
Zhou FL; Meng S; Zhang WG; Wei YC; Cao XM; Bai GG; Wang BY
Vaccine; 2010 Aug; 28(37):5939-46. PubMed ID: 20619381
[TBL] [Abstract][Full Text] [Related]
31. Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs.
Broen K; Greupink-Draaisma A; Fredrix H; Schaap N; Dolstra H
Bone Marrow Transplant; 2012 Sep; 47(9):1229-34. PubMed ID: 22246088
[TBL] [Abstract][Full Text] [Related]
32. [Clinical efficacy of immunotherapy of dendritic cell and cytokine-induced killer cell combined with chemotherapy for treatment of multiple myeloma].
Zhong GC; Yan B; Sun Y; Zhang XY; Chen J; Su Y; Sun HP; Zhu B
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1000-3. PubMed ID: 23363790
[TBL] [Abstract][Full Text] [Related]
33. Current role of immunotherapy in multiple myeloma.
Hájek R; Adam Z; Krivanová A; Doubek M; Korístek Z; Vorlícek J
Acta Med Austriaca; 1998; 25(3):79-85. PubMed ID: 9816399
[TBL] [Abstract][Full Text] [Related]
34. Current Strategies for the Immunotherapy of Multiple Myeloma.
Luetkens T; Yousef S; Radhakrishnan SV; Atanackovic D
Oncology (Williston Park); 2017 Jan; 31(1):55-63. PubMed ID: 28090624
[TBL] [Abstract][Full Text] [Related]
35. Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma.
Gorschlüter M; Ziske C; Glasmacher A; Schmidt-Wolf IG
Clin Cancer Res; 2001 Aug; 7(8):2195-204. PubMed ID: 11489792
[TBL] [Abstract][Full Text] [Related]
36. Vaccination of multiple myeloma: Current strategies and future prospects.
Allegra A; Penna G; Innao V; Greve B; Maisano V; Russo S; Musolino C
Crit Rev Oncol Hematol; 2015 Nov; 96(2):339-54. PubMed ID: 26123319
[TBL] [Abstract][Full Text] [Related]
37. Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma.
Arnason J; Avigan D
Immunotherapy; 2012 Oct; 4(10):1043-51. PubMed ID: 23148756
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy strategies for multiple myeloma: the present and the future.
Locke FL; Nishihori T; Alsina M; Kharfan-Dabaja MA
Immunotherapy; 2013 Sep; 5(9):1005-20. PubMed ID: 23998734
[TBL] [Abstract][Full Text] [Related]
39. Active immunotherapy of multiple myeloma.
Houet L; Veelken H
Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
[TBL] [Abstract][Full Text] [Related]
40. T cell-based targeted immunotherapies for patients with multiple myeloma.
Wang L; Jin N; Schmitt A; Greiner J; Malcherek G; Hundemer M; Mani J; Hose D; Raab MS; Ho AD; Chen BA; Goldschmidt H; Schmitt M
Int J Cancer; 2015 Apr; 136(8):1751-68. PubMed ID: 25195787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
